Competitive Strategy of Alphapharm, Estia Health and G8 Education

Running head: COMPETITIVE STRATEGY OF ALPHAPHARM, ESTIA HEALTH AND G8 EDUCATION
COMPETITIVE STRATEGY OF ALPHAPHARM, ESTIA HEALTH AND G8 EDUCATION
Name of the Student
Name of the University
Author note

1
COMPETITIVE STRATEGY OF ALPHAPHARM, ESTIA HEALTH AND G8 EDUCATION
Industry: Pharmaceutical
The pharmaceutical industry in Australia has witnessed an increasing competitive market
in the recent years. This is due to the technological advancements witnessed in the world of
medical sciences. Further, the increasing inspection from payers, the community and the
regulatory bodies have also compelled the pharma industries to rethink their strategies and
policies in order to survive. It is however, also true that the industry in Australia has witnessed
great boon over the past few decades as investors beyond the country are also showing interest in
the industry. In a recent survey by PwC, it was revealed that 45% of the people related to this
industry consider the m-health and e-health are the potential competitive advantages that will
benefit the industry in future.
Company: Alphapharm
Overview
A generic drug manufacturing company based in Australia, Alphapharm is owned by the
Mylan Pharmaceuticals of United States (Mylan.com.au, 2018). The company manufactures a
variety of generic drugs that is exported to more than fifty countries across the globe. The
company started operating in Australia in the year 1982 and has been among the top three
pharma companies in the country. In fact, as per the reports of the Australian government’s
industry data, it is the biggest drug manufacturing and selling Company in the country with 20%
share in the market (Industry.gov.au, 2018).
Competitive strategy

2
COMPETITIVE STRATEGY OF ALPHAPHARM, ESTIA HEALTH AND G8 EDUCATION
The company forms its strategies based on its three most important stakeholders that
include the doctors, the pharmacists and the consumers. One of Alphapharm’s biggest strategies
is its compliance with the policy of generic substitution (Mylan.com.au, 2018). The company is
probably the only in Australia that supplies generic medicines to the people and upholds generic
substitution. It follows the simple strategy to benefit all three of its stakeholders as mentioned. In
case of the doctors, the company has a separate force that gives every detail about the generic
substitution to the doctors thus helping them adapt to adopt this revolutionary idea. With regards
to the pharmacists, Alphapharm delivers numerous value-added services to the pharmacies and
that makes it the only company to do so. Lastly, the company has a separate and unqie strategy
for its consumers. To being with, it is the only pharma company that advertises on all forms of
media, be it television, print, radio or the social media.
The success of its competitive strategy is evident from its positioning in the ASX list of
top pharma companies in the country. In addition, the acquisitions made by the company over
the last few years including the latest in Mumbai, India prove its success.
Industry: Aged care
The aged care industry in Australia is abounding with opportunities for companies to
cash in and do business. The need for this industry in Australia is rising each year as the
country’s population is ageing. Many implications of this fact concern the Australian economy
and its society. The government is aware of this fact and has made provisions for the systematic
planning of providing home care and residential care for the aged population. However, the
industry continues to waver in trajectories unchartered as the aged care providers face
innumerable challenges as well as opportunities.